C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 17/02 (2006.01) A61K 38/26 (2006.01) A61K 47/48 (2006.01) C07K 14/605 (2006.01)
Patent
CA 2754350
Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half- life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist, are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.
La présente invention concerne des analogues peptidiques de l'oxyntomoduline (OXM, glucagon-37), qui ont été modifiés afin d'être résistants au clivage et à l'inactivation par la dipeptidyl-peptidase IV (DPP-IV) et afin d'augmenter la demi-vie in vivo de l'analogue peptidique tout en permettant à ce dernier d'agir comme un agoniste du récepteur double du GLP-1/glucagon (GCGR). Les analogues peptidiques sont utiles pour le traitement de troubles métaboliques tels que le diabète et l'obésité.
Bianchi Elisabetta
Capito Elena
Carrington Paul E.
Dimarchi Richard
Eiermann George J.
Indiana University Research And Technology Corporation
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.
Merck Sharp & Dohme Corp.
Robic
LandOfFree
Oxyntomodulin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxyntomodulin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxyntomodulin analogs will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1824487